| Identification | Back Directory | [Name]
N-[[[[(4S)-3-(4-Chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazol-1-yl][[[4-(trifluoromethyl)phenyl]sulfonyl]amino]methylene]amino]iminomethyl]acetamide | [CAS]
2712480-46-9 | [Synonyms]
N-[[[[(4S)-3-(4-Chlorophenyl)-4,5-dihydro-4-phenyl-1H-pyrazol-1-yl][[[4-(trifluoromethyl)phenyl]sulfonyl]amino]methylene]amino]iminomethyl]acetamide | [Molecular Formula]
C26H22ClF3N6O3S | [MOL File]
2712480-46-9.mol | [Molecular Weight]
591.01 |
| Hazard Information | Back Directory | [Uses]
Monlunabant ((S)-MRI-1891) is an orally active antagonist for cannabinoid receptor 1 (CB1), binds to hCB1 and hCB2 with Ki of 0.3 nM and 613 nM[1]. | [in vivo]
Monlunabant (1-10 mg/kg, po for 6-28 days) improves obesity-related insulin resistance in C57Bl/6J wildtype mouse models[1]. | Animal Model: | C57Bl/6J wildtype mouse models[1] | | Dosage: | 1-10 mg/kg | | Administration: | po for 6-28 days | | Result: | Reduced appetite and body weight, improved obesity-induced insulin resistance and glucose tolerance. |
| [References]
[1] Liu Z, et al., Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB1R) Antagonist. ACS Pharmacol Transl Sci. 2021 Apr 8;4(3):1175-1187. DOI:10.1021/acsptsci.1c00048
[2] Ghosh A, et al., A peripherally restricted cannabinoid-1 receptor inverse agonist promotes insulin secretion and protects from cytokine toxicity in human pancreatic islets. Eur J Pharmacol. 2023 Apr 5;944:175589 DOI:10.1016/j.ejphar.2023.175589 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|